603368 柳药集团
2025/09 - 九个月
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入15,758,037-1.47%21,182,45420,811,90319,052,83117,134,823
减:营业总成本14,995,915-0.57%20,166,80619,726,39318,126,74116,360,252
    其中:营业成本14,043,759-0.48%18,774,82318,337,66516,860,77815,178,672
               财务费用158,726-9.93%235,205249,462220,168204,128
               资产减值损失------------
公允价值变动收益------------
投资收益249-2,382.23%(95)(706)7,4121,993
    其中:对联营企业和合营企业的投资收益(4)--(132)(715)(189)--
营业利润754,347-11.76%1,003,5981,043,683890,061753,086
利润总额748,512-12.63%1,003,1361,043,381890,401754,680
减:所得税费用94,556-14.92%135,602136,777131,426113,595
净利润653,956-12.28%867,534906,604758,976641,085
减:非控股权益8,243-72.18%12,66257,01257,45877,267
股东净利润645,713-9.81%854,872849,592701,518563,817

市场价值指针
每股收益 (元) *1.630-12.83%2.2102.3501.9401.560
每股派息 (元) *----0.7510.6000.5080.480
每股净资产 (元) *19.3170.90%19.11017.84716.05714.646
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容